Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 1990 May;36:955–959.

Prognosis of Common Cancers

Peter H Geggie
PMCID: PMC2280477  PMID: 21233968

Abstract

Four cancers in each sex account for nearly 60% of all cases. Lung cancer therapy is stymied by a lack of effective agents, but can be prevented by a smoking cessation program. Breast cancer is far too prevalent, but has the best response rate to drugs and the best palliation of any of these tumours. Prostate cancer, once androgen deprivation has failed, is untreatable. Colorectal cancer therapy after years of inactivity is now exciting, while pancreas cancer remains almost untreatable. All Canadian patients should be encouraged to participate in clinical trials when appropriate.

Keywords: epidemiology, family medicine, oncology, prognosis

Full text

PDF
955

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonadonna G., Valagussa P. Current status of adjuvant chemotherapy for breast cancer. Semin Oncol. 1987 Mar;14(1):8–22. [PubMed] [Google Scholar]
  2. De Vita V. T., Jr Breast cancer therapy: exercising all our options. N Engl J Med. 1989 Feb 23;320(8):527–529. doi: 10.1056/NEJM198902233200812. [DOI] [PubMed] [Google Scholar]
  3. DeCosse J. J. Early cancer detection. Colorectal cancer. Cancer. 1988 Oct 15;62(8 Suppl):1787–1790. doi: 10.1002/1097-0142(19881015)62:1+<1787::aid-cncr2820621317>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  4. Fielding L. P., Phillips R. K., Hittinger R. Factors influencing mortality after curative resection for large bowel cancer in elderly patients. Lancet. 1989 Mar 18;1(8638):595–597. doi: 10.1016/s0140-6736(89)91618-8. [DOI] [PubMed] [Google Scholar]
  5. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., Dimitrov N. V., Wolmark N., Wickerham D. L., Fisher E. R. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989 Feb 23;320(8):479–484. doi: 10.1056/NEJM198902233200802. [DOI] [PubMed] [Google Scholar]
  6. Fisher B., Redmond C., Dimitrov N. V., Bowman D., Legault-Poisson S., Wickerham D. L., Wolmark N., Fisher E. R., Margolese R., Sutherland C. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med. 1989 Feb 23;320(8):473–478. doi: 10.1056/NEJM198902233200801. [DOI] [PubMed] [Google Scholar]
  7. Fisher B., Redmond C., Poisson R., Margolese R., Wolmark N., Wickerham L., Fisher E., Deutsch M., Caplan R., Pilch Y. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989 Mar 30;320(13):822–828. doi: 10.1056/NEJM198903303201302. [DOI] [PubMed] [Google Scholar]
  8. Ginsburg A. D., Perrault D. J., Pritchard K. I., Browman G. P., McCulloch P. B., Skillings J. Systemic adjuvant therapy for node-negative breast cancer. CMAJ. 1989 Sep 1;141(5):381–387. [PMC free article] [PubMed] [Google Scholar]
  9. Hickey D., Cant J., Soloway M. S. Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation. Urology. 1988 Jan;31(1):38–40. doi: 10.1016/0090-4295(88)90569-9. [DOI] [PubMed] [Google Scholar]
  10. Ishikawa S., Soloway M. S., Van der Zwaag R., Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol. 1989 May;141(5):1139–1142. doi: 10.1016/s0022-5347(17)41193-1. [DOI] [PubMed] [Google Scholar]
  11. Jewett H. J. Prostatic cancer: a personal view of the problem. J Urol. 1984 May;131(5):845–849. doi: 10.1016/s0022-5347(17)50677-1. [DOI] [PubMed] [Google Scholar]
  12. Johnston M. R. Selecting patients with lung cancer for surgical therapy. Semin Oncol. 1988 Jun;15(3):246–254. [PubMed] [Google Scholar]
  13. Mannell A., van Heerden J. A., Weiland L. H., Ilstrup D. M. Factors influencing survival after resection for ductal adenocarcinoma of the pancreas. Ann Surg. 1986 Apr;203(4):403–407. doi: 10.1097/00000658-198604000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McGuire W. L. Adjuvant therapy of node-negative breast cancer. N Engl J Med. 1989 Feb 23;320(8):525–527. doi: 10.1056/NEJM198902233200811. [DOI] [PubMed] [Google Scholar]
  15. Naruke T., Goya T., Tsuchiya R., Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988 Sep;96(3):440–447. [PubMed] [Google Scholar]
  16. O'Connell M. J., Gunderson L. L., Fleming T. R. Surgical adjuvant therapy of rectal cancer. Semin Oncol. 1988 Apr;15(2):138–145. [PubMed] [Google Scholar]
  17. Pritchard K. I., Sutherland D. J. The use of endocrine therapy. Hematol Oncol Clin North Am. 1989 Dec;3(4):765–805. [PubMed] [Google Scholar]
  18. Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol. 1988 Aug;15(4):371–389. [PubMed] [Google Scholar]
  19. Schellhammer P. F., Whitmore R. B., 3rd, Kuban D. A., el-Mahdi A. M., Ladaga L. A. Morbidity and mortality of local failure after definitive therapy for prostate cancer. J Urol. 1989 Mar;141(3):567–571. doi: 10.1016/s0022-5347(17)40896-2. [DOI] [PubMed] [Google Scholar]
  20. Seifter E. J., Ihde D. C. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol. 1988 Jun;15(3):278–299. [PubMed] [Google Scholar]
  21. Spiegelman D., Maurer L. H., Ware J. H., Perry M. C., Chahinian A. P., Comis R., Eaton W., Zimmer B., Green M. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol. 1989 Mar;7(3):344–354. doi: 10.1200/JCO.1989.7.3.344. [DOI] [PubMed] [Google Scholar]
  22. Theve N. O., Pousette A., Carlström K. Adenocarcinoma of the pancreas--a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol. 1983 Sep;9(3):193–197. [PubMed] [Google Scholar]
  23. Tønnesen K., Kamp-Jensen M. Antiestrogen therapy in pancreatic carcinoma: a preliminary report. Eur J Surg Oncol. 1986 Mar;12(1):69–70. [PubMed] [Google Scholar]
  24. Wong A., Chan A., Arthur K. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):749–750. [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES